Clinical Trial Update: AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of AMD3100 (plerixafor) as a sensitizing agent in allogeneic blood or marrow transplant for chemotherapy-resistant pediatric acute leukemias; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• Plerixafor (Mozobil) (plerixafor)

Snippet

Sponsor: Emory University | Conditions: Pediatric Acute Myeloblastic Leukemia, Relapsed, Pediatric Acute Lymphoblastic Leukemia, Relapsed | Phase 1 | Status: TERMINATED